Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 19 May 2023

Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells

in Cancer Molecular Targets and Therapeutics

Yulu Wang
Amit Sharma
Fangfang Ge
Peng Chen
Yu Yang
Hongjia Liu
Hongde Liu
Chunxia Zhao
Lovika Mittal
Shailendra Asthana

Frontiers in Oncology

doi 10.3389/fonc.2023.1157366

3,635 views
5 citations

Original Research

Published on 18 May 2023

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

in Cancer Molecular Targets and Therapeutics

Weili Yang
Haoran Qian
Litao Yang
Pengfei Wang
Hailong Qian
Binbin Chu
Zhuo Liu
Jingyu Sun
Dan Wu
Lifeng Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1180795

1,831 views
2 citations

Mini Review

Published on 18 May 2023

Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation

in Cancer Molecular Targets and Therapeutics

Shraddha M. Dalwadi
Andrew Hunt
Mark D. Bonnen
Yohannes T. Ghebre

Frontiers in Oncology

doi 10.3389/fonc.2023.1198284

2,587 views
8 citations

Original Research

Published on 18 May 2023

CEP55 as a promising biomarker and therapeutic target on gallbladder cancer

in Cancer Molecular Targets and Therapeutics

Maotuan Huang
Fuxiu Zhong
Mingyuan Chen
Lingju Hong
Weihong Chen
Xiahenazi Abudukeremu
Feifei She
Yanling Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1156177

2,554 views
7 citations

Original Research

Published on 16 May 2023

Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics

in Cancer Molecular Targets and Therapeutics

Yiren Yang
Qingyang Pang
Meimian Hua
Zhao Huangfu
Rui Yan
Wenqiang Liu
Wei Zhang
Xiaolei Shi
Yifan Xu
Jiazi Shi

Frontiers in Oncology

doi 10.3389/fonc.2023.1170567

3,669 views
12 citations

Case Report

Published on 16 May 2023

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

in Cancer Molecular Targets and Therapeutics

Yishi Zhang
Wan He
Ke Zhan
Luobin Zhang
Hua Cao
Ruilian Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1153233

1,867 views
1 citation

Case Report

Published on 12 May 2023

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

in Cancer Molecular Targets and Therapeutics

Hai Pan
Linlin Zhang
Fanlu Meng
Shasha Guan
Diansheng Zhong

Frontiers in Oncology

doi 10.3389/fonc.2023.1159308

1,987 views
2 citations

Original Research

Published on 12 May 2023

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

in Cancer Molecular Targets and Therapeutics

Mark Uhlik
Daniel Pointing
Seema Iyer
Luka Ausec
Miha Štajdohar
Robert Cvitkovič
Matjaž Žganec
Kerry Culm
Valerie Chamberlain Santos
Bronislaw Pytowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1158345

4,796 views
4 citations

Review

Published on 10 May 2023

Gas6/AXL pathway: immunological landscape and therapeutic potential

in Cancer Molecular Targets and Therapeutics

Xiaoqian Zhai
Dan Pu
Rulan Wang
Jiabi Zhang
Yiyun Lin
Yuqing Wang
Ni Zhai
Xuan Peng
Qinghua Zhou
Lu Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1121130

10,143 views
11 citations

Original Research

Published on 09 May 2023

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

in Cancer Molecular Targets and Therapeutics

Shicheng Yang
Allen Green
Needa Brown
Alexis Robinson
Merline Senat
Bryanna Testino
Daniela M. Dinulescu
Srinivas Sridhar

Frontiers in Oncology

doi 10.3389/fonc.2023.1175617

3,635 views
4 citations

Original Research

Published on 09 May 2023

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity

in Cancer Molecular Targets and Therapeutics

Ingo Andus
Friedrich Prall
Michael Linnebacher
Christina S. Linnebacher

Frontiers in Oncology

doi 10.3389/fonc.2023.1089681

3,303 views
1 citation

Review

Published on 09 May 2023

The role of fibroblast growth factor 18 in cancers: functions and signaling pathways

in Cancer Molecular Targets and Therapeutics

Yiming Zhou
Sizheng Sun
Tao Ling
Yongzhen Chen
Rongzhong Zhou
Qiang You

Frontiers in Oncology

doi 10.3389/fonc.2023.1124520

3,282 views
7 citations

Original Research

Published on 08 May 2023

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer

in Cancer Molecular Targets and Therapeutics

Gelareh Vahabzadeh
Solmaz Khalighfard
Ali Mohammad Alizadeh
Mahsa Yaghobinejad
Mahta Mardani
Tayebeh Rastegar
Mahmood Barati
Morad Roudbaraki
Ebrahim Esmati
Mohammad Babaei

Frontiers in Oncology

doi 10.3389/fonc.2023.1142275

2,016 views
1 citation

Review

Published on 05 May 2023

The emerging roles of Hedgehog signaling in tumor immune microenvironment

in Cancer Molecular Targets and Therapeutics

Juan Wang
Baiping Cui
Xiaojie Li
Xinyue Zhao
Taomin Huang
Xiaolei Ding

Frontiers in Oncology

doi 10.3389/fonc.2023.1171418

5,518 views
16 citations

Case Report

Published on 02 May 2023

The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report

in Cancer Molecular Targets and Therapeutics

Shujuan Fu
Zhiying Wang
Cunya Li
Yun Li
Ke Zhang
Zhixian Zhong
Yi Zhong

Frontiers in Oncology

doi 10.3389/fonc.2023.1094770

2,577 views
6 citations

Original Research

Published on 01 May 2023

A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration

in Cancer Molecular Targets and Therapeutics

Yan Feng
Fengying Tao
Han Qiao
Huaping Tang

Frontiers in Oncology

doi 10.3389/fonc.2023.1159725

3,725 views
8 citations

Navigation group

Articles

Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation

CEP55 as a promising biomarker and therapeutic target on gallbladder cancer

Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

Gas6/AXL pathway: immunological landscape and therapeutic potential

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity

The role of fibroblast growth factor 18 in cancers: functions and signaling pathways

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer

The emerging roles of Hedgehog signaling in tumor immune microenvironment

The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report

A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration